NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
91.30
+1.54 (+1.72%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close89.76
Open91.31
Bid91.20 x 900
Ask0.00 x 900
Day's Range90.98 - 91.63
52 Week Range64.78 - 91.63
Volume2,238,855
Avg. Volume2,696,523
Market Cap209.881B
Beta (3Y Monthly)0.54
PE Ratio (TTM)17.31
EPS (TTM)5.27
Earnings DateN/A
Forward Dividend & Yield2.83 (3.16%)
Ex-Dividend Date2019-03-04
1y Target Est99.50
Trade prices are not sourced from all markets
  • Reuters10 hours ago

    Online pharmacy flags possible new impurity in blood pressure drug

    Online pharmacy Valisure reported that it found a new cancer-causing impurity in some versions of widely prescribed blood pressure medicine valsartan, but U.S. regulators said on Tuesday that the amount in the drugs was well below levels deemed to be potentially harmful. Connecticut-based Valisure informed the U.S. Food and Drug Administration in a citizen petition https://www.regulations.gov/document?D=FDA-2019-P-2869-0001 last week that it had found through its own testing an impurity called dimethylformamide (DMF) in some batches of the drug. Valisure analyzed valsartan from multiple manufacturers including Novartis AG and several generic manufacturers.

  • Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
    Zacks18 hours ago

    Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

    Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

  • Moody's18 hours ago

    Alcon Inc. -- Moody's assigns Baa2 ratings to Alcon Inc.'s unsecured debt facilities

    Moody's Investors Service ("Moody's") has assigned a Baa2 rating to Alcon Inc.'s ("Alcon" or "the company") facilities. The loans are senior unsecured obligations of Alcon Inc..The proceeds from the above facilities were used alongside a $500 million 3-year senior unsecured term loan A, a $1.5 billion bridge-to-bond senior unsecured term loan and around $300 million equivalent local drawn lines to fund a $3,000 million payment to Novartis AG (A1 stable) and have a cash balance of approximately $500 million at closing of the spin-off from Novartis AG in April 2019.

  • Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
    Zacks20 hours ago

    Roche's Rozlytrek Gets Approval in Japan for Solid Tumors

    Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.

  • J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
    Zacks2 days ago

    J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

    J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

  • Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
    Zacks2 days ago

    Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

    Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

  • Financial Times5 days ago

    Bluebird Bio prices gene therapy at nearly $1.8m

    Bluebird Bio plans to price a new gene therapy for people with an inherited blood disorder at almost $1.8m per patient, and will try to persuade European healthcare systems to shell out for it by promising to only seek full payment if it works. Healthcare systems will pay an initial instalment of €315,000 but will only pay more instalments if the treatment helps the patient avoid blood transfusions. The Boston-based biotech start-up’s drug is part of a class of new transformative therapies that need to be administered only once and apply to a small patient population.

  • Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
    Zacks6 days ago

    Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris

    Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.

  • Top Analyst Reports for Visa, Netflix & Accenture
    Zacks6 days ago

    Top Analyst Reports for Visa, Netflix & Accenture

    Top Analyst Reports for Visa, Netflix & Accenture

  • Ligand Inks Oncology Drug Discovery Deal With PhoreMost
    Zacks6 days ago

    Ligand Inks Oncology Drug Discovery Deal With PhoreMost

    Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.

  • Barrons.com6 days ago

    A Stock Fund Challenges the Definition of Growth. It’s Paying Off.

    Elisa Mazen, who co-manages the $1.6 billion ClearBridge International Growth fund, isn’t afraid to take a broad definition of growth to find the best opportunities.

  • Roche's Rituxan Gets Priority Review for Blood Disorder
    Zacks7 days ago

    Roche's Rituxan Gets Priority Review for Blood Disorder

    Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.

  • Novartis Reports Data on Cosentyx for Psoriatic Arthritis
    Zacks7 days ago

    Novartis Reports Data on Cosentyx for Psoriatic Arthritis

    Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.

  • Stoke Therapeutics boosts IPO goal by 40 percent
    American City Business Journals8 days ago

    Stoke Therapeutics boosts IPO goal by 40 percent

    Stoke now hopes to raise $123 million when it launches on the Nasdaq market in the coming weeks, according to documents newly filed with the SEC. It originally had filed plans for an $86.25 million initial public offering last month. Stoke could be the fifth Massachusetts biotech to go public this year.

  • Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
    Zacks9 days ago

    Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug

    Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

  • Moody's9 days ago

    Curium Bidco S.a.r.l -- Moody's assigns B2 CFR to Curium Bidco S.a.r.l.; outlook stable

    Moody's Investors Service has today assigned a B2 corporate family rating (CFR) and a B2-PD probability of default rating (PDR) to radiopharmaceutical products provider Curium Bidco S.a.r.l.. Concurrently, Moody's has assigned B2 ratings to the proposed senior secured first lien term loans B maturing in 2026, split into a €485 million equivalent US dollar-denominated tranche and a €250 million Euro-denominated tranche. Moody's has also assigned a B2 rating to the proposed pari passu ranking €120 million revolving credit facility (RCF) maturing in 2025. Senior secured first lien facilities shall be co-borrowed by Curium Bidco S.a.r.l., Curium Netherlands B.V. and Curium US Holdings LLC. The outlook is stable.

  • Roche Receives FTC Request for Further Data on Spark Buyout
    Zacks9 days ago

    Roche Receives FTC Request for Further Data on Spark Buyout

    Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.

  • Celgene's Filing for Ozanimod Accepted for Review in US/EU
    Zacks12 days ago

    Celgene's Filing for Ozanimod Accepted for Review in US/EU

    The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

  • Benzinga12 days ago

    Sanofi's Leadership Transition: What You Need To Know

    With big pharma companies grappling with fundamental as well as geopolitical issues — including aging pipelines, key blockbuster drugs going off patent and a U.S. clampdown on drug pricing — many have turned to new leadership in recent years to reinvigorate growth. Sanofi has a mandatory 65-year-old retirement age for its CEO.

  • New Sanofi CEO 2019: 8 Things to Know About Paul Hudson
    InvestorPlace12 days ago

    New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

    There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring.Source: Shutterstock Here's what you need to know about Sanofi's (NASDAQ:SNY) new CEO. * The new Sanofi CEO is Paul Hudson. * He will be taking over the role of CEO from Brandicourt starting on Sept. 1, 2019. * Hudson's most recent work includes serving as the CEO of Novartis Pharmaceuticals (NYSE:NVS) and being a member on the Novartis Executive Committee. * The new Sanofi CEO also has plenty of experience working with pharmaceutical companies over the last 28 years. * Some of his major previous employers include Schering Plough, Astra Zeneca (NYSE:AZN) and Novartis. * This has given him plenty of experience working in the markets of the U.S., Japan and Europe. * It has also awarded him the experience needed to handle leadership through his previous management roles. * Paul Hudson will also be moving to Paris, France to serve in his role as CEO of the company, which has its headquarter there. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% Serge Weinberg, Chairman of the Board of Directors for Sanofi, has this to say about the change.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world."SNY stock was up 5% as of Friday morning. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post New Sanofi CEO 2019: 8 Things to Know About Paul Hudson appeared first on InvestorPlace.

  • Here’s What Hedge Funds Think About Novartis AG  (NVS)
    Insider Monkey12 days ago

    Here’s What Hedge Funds Think About Novartis AG (NVS)

    Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Sanofi Taps Novartis Executive as CEO in Race for New Drugs
    Bloomberg12 days ago

    Sanofi Taps Novartis Executive as CEO in Race for New Drugs

    Bringing in Paul Hudson as its next chief executive officer will help the French pharma giant bolster its pipeline of medicines and deal with growing U.S. pressure on drug prices. The 51-year-old British executive will take over in September from Olivier Brandicourt, 63, who’s retiring. Hudson has led Novartis’s pharma unit since 2016 and is credited with launching key medicines such as psoriasis treatment Cosentyx, which may become its top product this year with a projected $3.5 billion in sales.

  • Novartis Appoints New Pharma Unit Head, Gives Other Updates
    Zacks12 days ago

    Novartis Appoints New Pharma Unit Head, Gives Other Updates

    Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.

  • Benzinga12 days ago

    The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...

  • Financial Times12 days ago

    Sanofi appoints top Novartis executive as new chief

    French drugmaker Sanofi has announced that a top executive from Swiss rival Novartis will succeed Olivier Brandicourt as CEO. Paul Hudson, who was most recently chief executive of the Novartis pharmaceuticals business and member of the executive committee of the overall group, will take over on September 1. since Sanofi’s diabetes treatments lost patent protection and came under pressure from cheaper rivals.